Successful Regulatory Exchange on 3D Mucosal Models for Vaccine Development at RIVM
Newsroom
Check on Inno4Vac latest news
- Jun 4
Inno4Vac interim review: advancing scientific and technological progress
- Jun 3
Face to face VAXPRED meeting 31st May 2024
- Feb 22
Four Key Reports highlighting regulatory and ethical aspects of the Controlled Human Infection Models
- Jan 31
New findings on vaccine efficacy prediction: comprehensive antibody repertoire profiling
- Jan 16
Regulatory engagement – continuing dialogue between ST4 model developers and EMA QIG
- Oct 18, 2023
Annual Meeting 2023 Inno4Vac: innovations to accelerate vaccine development and manufacture
- Oct 16, 2023
Online platform on bio-manufacturing: workshop on integrating in silico models of unit operations
- Oct 4, 2023
Towards controlled human Clostridioides difficile colonization and infection
- Sep 11, 2023
1st Inno4Vac newsletter is out!
- Aug 10, 2023
The Inno4Vac Scientific and Ethics Advisory Committee has been appointed
- Jun 28, 2023
A regulatory exchange on diversity and standardisation of 3D mucosal models for vaccine development
- May 17, 2023
Subtopic 1 VAXPRED meeting on 8-9 May 2023
- Nov 16, 2022
Annual Meeting 2022 Inno4Vac: innovations to accelerate vaccine development and manufacture
- Dec 14, 2021
First CHIMICHURRI workshop: developing a strategy for new challenge flu and RSV strain selection
- Sep 29, 2021
Inno4Vac kick-off meeting brings together over 150 partners
- Jul 29, 2021
EVI to lead Inno4Vac, a new European public-private partnership to innovate vaccine development